Introduction
While the growing burden of allergic diseases (asthma, allergic rhinitis, food allergies, atopic dermatitis) has been apparent in Westernized countries for the last few decades, there is now mounting concern that billions of people will be affected as developing countries begin to show the same trends [1] . It is becoming increasingly urgent to define the causal pathways, and to develop better strategies to avert the processes that lead to these diseases. Strategies that reduce the risk (even slightly) or the severity of disease expression could have enormous impact in this global context. Although genetic studies will provide important information about biological pathways and potential mechanisms, environmental changes must be responsible for the recent epidemic rise in allergic disease with progressive Westernization. Environmental factors may also provide feasible and relatively noninvasive avenues for modifying or preventing the processes that lead to allergic disease. So far allergy prevention strategies have focused on allergen avoidance in early life and have been particularly disappointing [2] . There is a growing recognition that while allergen exposure is necessary for specific sensitization, these allergens are not responsible for the general increase in allergic propensity either at the individual or the society level. This suggests that other environmental changes are involved. Although changes with progressive Westernization are clearly complex and multifactorial, associated dietary changes have been identified as one important research priority.
Modern diets differ in many respects from more traditional diets, with more complex, processed and synthetic foods and less fresh fish, fruits and vegetables. As a result there have been many changes in the intakes of various dietary components. One change that has been identified is increased consumption of o-6 polyunsaturated fatty acids (n-6 PUFAs) and decreased consumption of o-3 PUFAs (n-3 PUFAs). While this review focuses on the specific role of n-3 PUFAs, this 'single component' approach may not fully address the 'composite effects' of diets and dietary changes (or interaction with other environmental factors). It remains essential to recognize the overall complexity of dietary changes in the wider context. Just as it appears that no single gene is responsible for allergy or asthma, it appears equally unlikely that a single environmental factor is responsible for the recent allergy crisis.
This specific interest in n-3 PUFAs arises from both epidemiological associations between declining intakes of n-3 PUFAs and rising allergic disease and the well characterized antiinflammatory effects of these fatty acids which provide very plausible biological mechanisms of effect [3, 4] . Here, we will examine the current evidence for a potential role of changing dietary intakes of n-3 PUFAs in the changing prevalence of allergic propensity and the role of these fatty acids in the treatment and prevention of allergic diseases.
Allergy and immune dysregulation: current perspectives
IgE-mediated allergic diseases are heterogeneous inflammatory conditions, which appear to arise from varying predisposing genetic and environmental factors in different individuals. This may account for the lack of clear causal genetic or environmental pathways. There is also accumulating evidence that tissue-specific manifestations of disease (such as airways disease) occur through independent processes in predisposed atopic individuals. Thus, conditions such as asthma are the culmination of both local epithelial dysfunction and generalized atopic predisposition. Environmental influences, including dietary factors, could therefore operate through a wide number of aspects of both local and general developmental processes.
While decades of research have provided a detailed knowledge of the immunological processes that underlie the acute allergic immune response, surprisingly little is known about how or why these inflammatory processes are initiated and why an increasing number of individuals are affected. Fundamental to addressing these issues is a more detailed understanding of early immune development, as it is now clear that initiating events occur during this critical early period [5] .
Although it is generally accepted that established allergic disease is the result of excessive and inappropriate type 2 T helper cell (Th2) responses to allergens, the previous notion that this is the result of a simple 'skewing' of immune responses away from 'normal' type 1 (Th1) responses has been called into question. Although there are clear parallels with the Th1/Th2 paradigm originally described in rodents [6, 7] , the role of this in human disease development is unclear. There is certainly a substantial body of evidence implicating several 'Th2' cytokines (IL-4, IL-5, IL-9, IL-13) in the development and expression of allergy and airways inflammation. Although 'deficient' Th1 function was initially proposed as an underlying factor, there is no conclusive evidence of impaired Th1 function in either established asthma or atopy [8, 9 . ,10 . . ]. In fact, many recent studies suggest that affected individuals are more generally responsive to allergens with increases in both Th1 and Th2 responses [9 . ,10
. . ], suggesting a breakdown of more fundamental common regulatory processes that affect many aspects of immune function. This also challenges the notion that modern environmental changes are having a 'Th2 skewing effect' by specifically promoting Th2 responses or inhibiting Th1 responses. Indeed, any potential beneficial effects of n-3 PUFAs in preventing or modifying allergic immune responses (discussed further below) do not appear to be operating through 'skewing' T-cell responses. Rather, these antiinflammatory fatty acids appear to be associated with suppression of both Th1 and Th2 cytokine responses (reviewed recently in [11] ). Thus, understanding the origins of allergic inflammation and identifying strategies for its prevention need to go beyond the original Th1/ Th2 paradigm.
Avenues of environmental influence: effects on immune regulatory pathways
More recently, it has been proposed that environmental changes have in some way modified regulatory systems such that they inadequately prevent over-expression of inappropriate Th1 and Th2 responses in predisposed individuals [12] . This model may also explain the otherwise paradoxical observation that 'Th1 diseases' (such as type 1 diabetes, Crohn's disease and multiple sclerosis) have also increased during the same period of the 'Th2 allergy epidemic' [13] . As a result of this perspective, there has been intense interest in aspects of the immune network with known homeostatic and immunomodulatory effects (particularly cells that produce key regulatory cytokines such as IL-10 and transforming growth factor-b) and how these might be influenced by environmental factors. Many cells produce these regulatory cytokines, but there has been particular interest in the role of antigen presenting cells (APCs) and regulatory T cells, which influence both the pattern and magnitude of effector T-cell signalling. While most research has focused on the environmental effects of microbial elements in this context, it is equally relevant to explore how other environmental factors may influence regulatory processes. Dietary n-3 PUFAs have well documented immunoregulatory effects [3, 4, 11] , although the mechanisms are not well understood.
Previous attempts to explain the immunological effects of n-3 PUFAs have largely focused on the ability of these fatty acids to suppress the production of the inflammatory prostaglandin E 2 (PGE 2 ). PGE 2 is produced from the n-6 PUFA arachidonic acid by the action of cyclooxygenase-2. When its intake is increased, the n-3 PUFA eicosapentaenoic acid (EPA) partly replaces arachidonic acid in the membranes of inflammatory cells [14] [15] [16] . This means that less arachidonic acid is available for PGE 2 production. Furthermore, EPA and docosahexaenoic acid (DHA) inhibit cyclooxygenase-2 activity [17] and decrease expression of the cyclooxygenase-2 gene [18, 19] . Thus, n-3 PUFAs decrease the production of PGE 2 by inflammatory cells [14, [20] [21] [22] . The capacity for PGE 2 to suppress Th1 activity (e.g. IFN-g production) [23] [24] [25] [26] [27] , to indirectly favour Th2 differentiation [28, 29] and to promote IgE isotypeswitching [30] , suggests a potential role of n-3 PUFAs in countering the theoretical adverse Th1-Th2 balance in individuals with an allergic predisposition. This remains unproven, however, and the situation is undoubtedly more complex because PGE 2 also has some immunosuppressive effects on APCs that appear to be mediated by IL-10 [31 . ]. Furthermore, PGE 2 inhibits 5-lipoxygenase downregulating the production of the leukotrienes such as leukotriene B 4 (LTB 4 ) [32] that are mediators of allergic inflammation, and upregulating the production of lipoxins [33] that are considered to act to resolve inflammation [34] . It thus appears that the interactions between n-6 and n-3 PUFAs and immune function are likely to be much more complex than previously considered, and further mechanistic studies are clearly warranted.
In addition to effects on production of prostaglandins, n-3 PUFAs can regulate T-cell function directly through effects on cell membrane fluidity and consequent cell signalling and gene transcription (reviewed in [11] ). Furthermore, they may also modify T-cell effector function through effects on regulatory cell populations. Increasing the content of n-3 PUFAs in cell membranes reduces the capacity of APCs to present antigen to T cells (by inhibiting the upregulation of HLA class II receptors) [35] [36] [37] . These fatty acids also decrease production of cytokines by APCs, including the synthesis of IL-12, an important pro-Th1 cytokine [29] . These effects of n-3 PUFAs are generally related to reduced capacity for T-cell responses. However, there have not been any studies to directly address the specific effects of n-3 PUFAs on IL-10 and transforming growth factorb-associated regulatory pathways. If anything, n-3 PUFA supplementation appears to be associated with decreased IL-10 production in some [38,39
. . ,40] but not all [41] studies. This is also associated with decreases in the production of cytokines including tumor necrosis factor-a and IL-1 [14, 21, 22] , but effects on other cytokines are still not well documented. Clearly a better understanding of the effects of n-3 PUFAs is necessary to explore both causal and therapeutic pathways Evidence for a role of dietary fatty acids in the altering prevalence of allergic disease
The major dietary source of long-chain n-3 PUFAs is oily fish. Over the last few decades there has been a relative decline in the consumption of these fatty acids [42] and an increase in the consumption of the potentially more 'proinflammatory' n-6 PUFAs. Although there are epidemiological studies linking these dietary changes with the rise in allergic disease (reviewed in [28, 43] ), there is no definitive evidence of a causal link, and the inherent difficulty of performing studies to establish such causality will make it very difficult to prove. Associations between dietary exposures and immune development are of greatest interest in childhood when immune responses are developing. Perhaps the best known study to address this [44] observed that children who regularly consumed oily fish were significantly less likely to develop asthma (odds ratio 0.26), but there have been relatively few other studies to confirm this association. Allergic disease in childhood has also been associated with higher consumption of n-6 PUFAs (more margarine and less butter) [45] . Large international epidemiological studies have also described similar associations with reduced intakes of other dietary factors (cereals and rice) [46] , highlighting the need for a multifactorial approach as discussed above. To challenge the observed protective effects of oily fish, a large Japanese study [47 . .
] recently noted that increasing fish intake was associated with a significantly higher prevalence of asthma (odds ratio 1.117) after adjusting for age, gender, parental history of asthma, and other dietary intakes (vegetables and fruits). One other recent study in children [48] also linked higher dietary PUFA intakes with asthma risk (odds ratio 2.03). That study, however, relied on a crude questionnaire tool and did not address the separate effects of n-6 and n-3 PUFAs, making the results difficult to interpret. In general, because of the limitations of these population-based studies, attention is turning to well controlled intervention studies to examine potential effects of n-3 PUFAs in a more controlled manner (as discussed further below).
The role of n-3 fatty acids in treatment of established allergic diseases
A number of studies have demonstrated that supplementation of the diet with fish oil results in decreased generation of mediators of inflammation, such as leukotrienes B 4 [49] [50] [51] and C 4 [51, 52] , by leukocytes in individuals with allergic disease. Leukocyte chemotaxis is also decreased by fish oil supplementation [49, 50] . Despite these potentially clinically relevant effects on leukocyte responses, studies investigating the therapeutic benefits of n-3 PUFAs in established allergic disease have generally been disappointing. The most recent Cochrane systematic review [53 . . ] included nine randomized controlled trials comparing n-3 PUFA supplementation with placebo [49, 50, [54] [55] [56] [57] [58] or with n-6 PUFA supplementation [59] . Seven of the studies were conducted in adults and two [58, 59] in children. The review concluded that there is no evidence of consistent benefit of n-3 PUFAs in the management of asthma. It is worth noting, however, that a number of the studies not included in this Cochrane review (for varying reasons including nonrandomized controlled trials, supplementation duration less than 4 weeks, and n-3 PUFAs not of marine origin) did report clinical benefits in asthma [52, [60] [61] [62] [63] [64] [65] [66] . Furthermore, only two of the studies that were included were conducted in children. One of these [58] reported that fish oil supplementation was associated with improved asthma symptom scores and reduced medication usage. The authors of the other study in children [59] provided additional information for the Cochrane review, which also demonstrated a significant improvement in peak expiratory flow and asthma medication use after concurrent dietary manipulation and n-3 PUFA supplementation. While inconclusive, these observations highlight the need for further studies, particularly in children with asthma. There has been one further study of PUFA supplementation in asthma since the publication of the Cochrane review. This study used a mixture of 0.75 g g-linolenic acid and 0.5 g EPA daily for 4 weeks [67] . This intervention resulted in a significant reduction in LTB 4 biosynthesis after 4 weeks, but there were no clinical effects on asthma, although a longer follow up period is proposed by the authors.
Few studies have reported on the effects of n-3 PUFA supplementation on other allergic diseases. Some early reports [68] suggested that dietary supplementation with fish oil improved atopic dermatitis severity in adults, while others have found no effect [69] . One more recent study reported improvement in severe atopic dermatitis using intravenous administration of n-3 PUFAs [70] .
The role of n-3 fatty acids in prevention of allergic disease
While there may not be strong evidence that n-3 PUFAs have a major therapeutic role in established disease, especially in adults, there remains considerable interest in the role of these fatty acids in early life for the prevention of disease. It is possible that the immunomodulatory benefits of n-3 PUFAs may be greater during critical stages of early immune development before allergic responses are established. Two recently published studies address this issue for the first time. The first of these [71 . . ] examined the role of postnatal fish oil supplementation (500 mg DHA-rich fish oil per day from weaning or from 6 months of age) in Australian children (n = 616) at high risk of allergic disease (affected parents or siblings). Although the only clinical follow up data currently available are at 18 months (n = 543), the authors reported that fish oil supplementation was associated with 9.8% absolute reduction (95% CI, 1.5-18.1; P = 0.02) in the prevalence of any wheeze and a 7.8% absolute reduction (95% CI, 0.5-15.1, P = 0.04) in the prevalence of wheeze of more than a week. Of interest, there was no effect on serum total IgE concentration, sensitization to foods, or atopic dermatitis, which are common manifestations of allergic disease in early infancy. Further follow up of this cohort will be of great interest, as wheezing in this early period is difficult to define. So far this group has not published any data on the immunologic effects of this intervention, which will clearly also be of great interest.
The other study to attempt allergy prevention by increasing early life exposure to n-3 PUFAs (also conducted in Australia) examined the effects of an antenatal intervention by giving fish oil supplements (or placebo) to allergic women during pregnancy [38,39
. . ,72
. .
]. The rationale for this approach was to provide a very early intervention in order to assess the effects on developing immune function in infants at high risk of allergic disease. This was based on previous observations that allergen-specific responses are already evident at birth, and that allergic disease is often manifest within the first months of life, suggesting that the processes that lead to allergic disease can be initiated very early in immune development [73, 74] . In this study 98 atopic women received fish oil (3.7 g n-3 PUFAs/day) or placebo from 20 weeks of gestation until delivery. Fish oil supplementation achieved significantly higher proportions of n-3 PUFAs in neonatal erythrocyte membranes compared with the control group (P50.001) [75] . The average concentration of the Th2 cytokine IL-13 in umbilical cord plasma was 65% lower in the fish oil group and there was an inverse relationship between the concentration of IL-13 and the DHA content of neonatal erythrocytes [72 . . ]. Neonatal mononuclear cell responses to all allergens tested also showed a consistent trend for all cytokines studied (IL-5, IL-13, IL-10, IFN-g) to be lower in the fish oil group (although this was statistically significant only for IL-10 in response to cat allergen) [39
. . ]. There were inverse relationships between the n-3 PUFA content of neonatal erythrocytes and cytokine responses [39
. . ]. Although these relationships were most significant for IFN-g and IL-10 responses, the same trends were seen for most other Th2 cytokines. Conversely, there were significant positive relationships between the n-6 PUFA content of neonatal erythrocytes and the cytokine responses [39
. . ]. These observations suggest that n-3 PUFAs in pregnancy have effects on neonatal immune function, although a larger study would have provided clearer answers. Although this study was not designed to examine clinical effects, it is worth noting that infants in the fish oil group were consistently less likely to develop clinical features including food allergy, recurrent wheeze, persistent cough, diagnosed asthma, angioedema, or anaphylaxis, compared with the control group [39
. . ]. Although there was no difference in the frequency of atopic dermatitis at 1 year of age, infants in the fish oil group had significantly less severe disease (OR 0.09; 95% CI, 0.01-0.94; P = 0.045). Children in the fish oil group were also three times less likely to have a positive skin prick test to egg at 1 year of age (OR 0.34; 95% CI 0.11-1.02; P = 0.055). Since 37.8% of infants in the control group and 17.1% in the fish oil group were sensitized to egg, this represents an absolute reduction of 20.7%, and in this population a relative risk reduction of 54.6% [39
. . ]. These differences were not statistically significant because of the study size (the study was 'powered' to look at immunologic rather than clinical outcomes). Nevertheless, this study provides useful justification for larger long-term studies. It is of interest that this study is suggestive of effects on early markers of infant allergic disease (sensitization to foods and atopic dermatitis), which were not seen in the study by Mihrshahi et al. [71 . . ], who began their fish oil intervention after 6 months of age. This may indicate that earlier interventions could be more effective in preventing early sensitization (and possibly the processes which lead on to aeroallergen sensitivity). This should be considered in further studies.
Future strategies: role of chemically engineered n-3 fatty acids in modifying immune function Advances in molecular technology could lead to the development of new antiinflammatory agents by chemically engineering PUFAs. Although native n-3 PUFAs inhibit mononuclear cell function, they can also stimulate the neutrophil respiratory burst in the context of inflammation, potentially limiting their antiinflammatory properties. A novel n-3 PUFA (b-oxa 21:3n-3) that has more selective immunologic effects, with stronger inhibition of T-cell activity than native n-3 PUFAs but without significant stimulation of the neutrophil respiratory burst, has been engineered [76] . Although there is no current therapeutic role for this and other such compounds, this illustrates another potential future avenue for approaching prevention and therapy of inflammatory diseases.
Conclusion
The well described immunomodulatory effects of n-3 PUFAs (both in vitro and in vivo) highlight the potential role of these dietary factors in preventing and treating allergic disease. While it will be difficult to prove a causal role of declining dietary n-3 PUFA intake in the increasing prevalence of allergic disease, intervention studies provide preliminary evidence that these fatty acids can modify developing immune responses and disease expression in early life. Larger longitudinal intervention studies are clearly warranted to confirm this observation. If confirmed, dietary recommendations could provide a safe, noninvasive strategy to reduce disease burden with relatively little cost. In the context of this growing worldwide health crisis, even small preventive effects could have a huge impact. . This study demonstrated that clinical food allergy correlated with ovalbuminspecific type 2 cytokine responses but was not associated with inability to produce ovalbumin-specific IFN-g. Rather, the atopic children had mixed type 2/type 1 responses to allergens. Furthermore, the development of clinical food tolerance was associated with persistent IL-10 and IFN-g responses to food, suggesting persistent 'regulatory' populations rather than clonal deletion of all food responsive T-cells. Consistent with other studies, atopic children in this study showed increased type 2 responses to both allergens and polyclonal stimulation compared with nonatopic children. Of note, this study demonstrated that while atopic children had reduced type 1 IFN-g to polyclonal stimulation, they actually had significantly higher IFN-g responses to the allergens. This is consistent with the findings of Ng et al. [9 . ] and suggests that while allergic infants have increased (type 1 and type 2) responsiveness to allergens, this coexists with a decreased capacity for polyclonal type 1 responses. The reason for this is unclear. . This study examined the effects of n-3 PUFA supplementation in pregnancy on early immune development in the same population described above. The focus of this paper was on a more detailed assessment of the in-vitro responsiveness of neonatal mononuclear cells to allergens and other stimuli. All neonatal cytokine (IL-5, IL-13, IL-10 and IFN-g) responses (to all allergens) tended to be lower in the fish oil group (statistically significant only for IL-10 in response to cat allergen). Although this study was not designed to examine clinical effects, infants in the fish oil group were three times less likely to have a positive skin prick test to egg at 1 year of age (OR 0.34, 95% CI 0.11-1.02, P = 0.055). Although there was no difference in the frequency of atopic dermatitis at 1 year of age, infants in the fish oil group also had significantly less severe disease (OR 0.09, 95% CI 0.01-0.94, P = 0.045). These data suggest potential reduction in subsequent infant allergy following maternal PUFA supplementation, but highlight the need for larger follow up studies to determine the significance in the longer term modification of allergic disease in children.
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